Half-Year Report on the Theradiag Liquidity Agreement with DSF Markets

Regulatory News :

Theradiag (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostics and in vitro diagnostics, today announced its half-year report on the liquidity agreement signed with DSF Markets.

The following resources were listed in the liquidity account on December 31, 2013:

• 36,456 Theradiag shares
• €143,750.20

As a reminder, during the last half year liquidity agreement on June 30, 2013, the following assets appeared on the liquidity account:

• 26,399 Theradiag shares
• €174,862.11

About Theradiag
Backed by its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of "customized treatment”, which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has some 50 employees.

For more information about Theradiag, please visit our website: www.theradiag.com